Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Monday, April 29th. The shares were sold at an average price of $17.92, for a total transaction of $215,040.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Joseph P. Lyssikatos also recently made the following trade(s):

• On Thursday, April 11th, Joseph P. Lyssikatos sold 30,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $751,200.00.
• On Monday, April 1st, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.60, for a total transaction of $223,200.00.
• On Thursday, February 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.42, for a total value of $197,040.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $22.65 on Friday. The company’s fifty day moving average is $17.42 and its two-hundred day moving average is $14.71. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -10.34 and a beta of 1.05.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently made changes to their positions in ELVN. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the third quarter worth $157,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Enliven Therapeutics in the 4th quarter worth about $66,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after acquiring an additional 1,029 shares during the period. Exchange Traded Concepts LLC lifted its position in Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after purchasing an additional 2,208 shares during the last quarter. Finally, AJOVista LLC acquired a new position in Enliven Therapeutics during the 4th quarter valued at about $28,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.